Effects of different doses of lithium on the central nervous system in the rat valproic acid model of autism.

Scientists studied whether lithium (a mood stabilizer) could help with autism-like behaviors in rats. They found that lithium improved social skills, memory, and reduced anxiety in the rats. The treatment also reduced brain inflammation and changed how genes work in important brain areas. While this is early research in animals, it suggests lithium might be helpful for some autism symptoms.

This preclinical study investigated lithium's effects on autism-like behaviors using a rat model induced by valproic acid (VPA). Researchers tested different lithium doses and found improvements in social cognition, social memory, and anxiety levels in treated rats. The study identified potential mechanisms including reduced neuroinflammation (decreased IL-6 levels and microglial activation in the hippocampus) and increased histone acetylation (H3K9). The optimal dose appeared to be 1.0 mmol/kg, which normalized microglial cell numbers in the hippocampus.

These findings suggest lithium may have neuroprotective effects and could potentially address core autism symptoms through anti-inflammatory pathways and epigenetic modifications.

Preliminary evidence suggests lithium may benefit autism symptoms through anti-inflammatory and epigenetic mechanisms. However, human trials are essential before clinical application. Current findings support further research into lithium's neuroprotective effects in autism spectrum disorders.

Animal model study limits direct applicability to humans. Sample size not reported. No information on study duration, control groups, or statistical methods. Optimal dosing for humans unclear. Long-term safety and efficacy data not provided.

Epidemiological studies have shown that low doses of lithium in the environment can have beneficial effects on mental health. Autism spectrum disorder, a neurodevelopmental disorder in which patients exhibit abnormal behaviors, pharmacological interventions usually relied on a range of psychotropic medications. However, such medications often produce severe side effects or are ineffective in symptoms. Finding alternative ways to improve abnormal behaviors in individuals with autism are warranted, in which case lithium may be a relatively safe and effective medication.

Lithium salt therapy is used to treat a variety of neuropsychiatric disorders and has neuroprotective effects. In this study, we investigated the effects of different doses of lithium on neurobehavioural disorders using the rat model of autism established by valproic acid (VPA) injection. Lithium was observed to have an ameliorative effect on the social cognitive, social memory and anxiety levels in the rat model of autism. Immunofluorescence staining showed that subchronic LiCl administration (1.0 mmol/kg) significantly reduced the number of Iba-1 positive cells in the CA1 region of the hippocampus in VPA group and brought it close to the levels of control group.

Significantly lower levels of the pro-inflammatory marker IL-6 were observed in the hippocampus and serum after lithium treatment. In addition, the lithium treatment increased the levels of H3K9 acetylation in the hippocampus of VPA-exposed rats. The results showed a defensive effect of environment-related lithium exposure doses on neurobehavioural deficits in the rat valproic acid model of autism, suggesting that it may be a potential drug for the treatment of autism.